PRME

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Nelsen RobertDirector, 10 Percent Owner: --75k shares Grant / ExerciseJun 5, 2026 $229.5K75k shares $3.06 $3.30

News

seekingalpha.comPrime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 5

globenewswire.comPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 3

globenewswire.comPrime Medicine to Present at Jefferies Global Healthcare Conferenceglobenewswire.comMay 28

zacks.comPrime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimateszacks.comMay 7

globenewswire.comPrime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.comMay 7

Trade PRME

About Prime Medicine, Inc.

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

CEO: Allan Reine
IPO Date: Oct 20, 2022

Market Data

Open: $2.99
High: $3.05
Low: $2.79
Volume: 2.4M
52W High: $6.94
52W Low: $1.40

Valuation

Market Cap: $520M
Enterprise Value: $571M

Financials

Free Cash Flow: $-167M
Revenue: $4.6M
Net Income: $-201M
Cash: $63M
Debt: $116M

Events

EarningsAug 6

EPS est. -0.24